A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSVdeltaG-ZEBOV GP) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE)
Phase of Trial: Phase II
Latest Information Update: 09 May 2017
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Pharmacodynamics
- 17 Dec 2016 Planned number of patients changed from 300 to 1000.
- 17 Dec 2016 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.
- 02 Dec 2016 Planned End Date changed from 1 Dec 2021 to 1 Oct 2021.